As a specialist cardiologist, Dr. Shelley possesses nearly 30 years of clinical experience in cardiovascular medicine, including interventional cardiology, echocardiography, and cardiac rehabilitation. She is the sole professional committee member from Hong Kong for the Chinese Psychosocial Oncology Society (C-POS). She participated in and assisted Professor Dayi Hu, Founding President of the Great Wall International Congress of Cardiology (GW-ICC), in establishing work related to Chinese cardiovascular rehabilitation medicine and cardiovascular psychology (known as Psycho-Cardiology). She also participated in the writing of China's first textbook on Psycho-cardiology. She has led or participated in numerous drug clinical trials, multi-center epidemiological studies, and drug registration processes.

As a specialist cardiologist, Dr. Shelley possesses nearly 30 years of clinical experience in cardiovascular medicine, including interventional cardiology, echocardiography, and cardiac rehabilitation. She is the sole professional committee member from Hong Kong for the Chinese Psychosocial Oncology Society (C-POS). She participated in and assisted Professor Dayi Hu, Founding President of the Great Wall International Congress of Cardiology (GW-ICC), in establishing work related to Chinese cardiovascular rehabilitation medicine and cardiovascular psychology (known as Psycho-Cardiology). She also participated in the writing of China's first textbook on Psycho-cardiology. She has led or participated in numerous drug clinical trials, multi-center epidemiological studies, and drug registration processes.

Since 2021, Dr. Shelley has fully overseen the establishment and operation of The Loop Institute of Innovative Translational Medicine and the Asia Academy of Anti-aging Research and Translational Medicine. This initiative aims to establish the first world-class comprehensive and interdisciplinary translational medicine R&D institute in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, themed on of anti-aging and age-related diseases. By establishing four translational platforms centered around geriatrics, chronic diseases, and related conditions, the project adds significant impetus to promoting Hetao Shenzhen-Hong Kong science and technology innovation, translational medicine development in the Hetao area, and scientific research cooperation, academic exchange, and development between Shenzhen and Hong Kong. These four platforms include: 1. Platform for Small Molecule Drug Screening and Research on Aging and Aging-related Diseases 2. Platform for Small Molecule Drug (SMD) Screening and Research on Aging and Aging-related Diseases 3. IVD, microfluidics and biochip development and clinical application platform for aging-related diseases 4. Loop Laboratory of Shenzhen Maternal and Child Health Medical Research Institute, Loop Subcenter of Shenzhen Clinical Medical Research Center for Obstetrics and Reproductive Diseases.